Efficacy and Safety of Risankizumab in Paediatric Patients With Psoriasis in the OptIMMize-1 Phase III Study.

Magnolo N, Lara WL, Reich A, Lara-Corrales I, Morita A, Bukhalo M, Vicente A, Anschutz T, Lyles RD, Madihlaba T, Unnebrink K, Ashley D, Sharma D, D'Cunha R, Paller AS

Open source

DOI: 10.1093/bjd/ljag403
Published: 2026 Sep 26
Container: The British journal of dermatology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/bjd/ljag403,
  title = {Efficacy and Safety of Risankizumab in Paediatric Patients With Psoriasis in the OptIMMize-1 Phase III Study.},
  author = {Magnolo N and Lara WL and Reich A and Lara-Corrales I and Morita A and Bukhalo M and Vicente A and Anschutz T and Lyles RD and Madihlaba T and Unnebrink K and Ashley D and Sharma D and D'Cunha R and Paller AS},
  year = {2026},
  journal = {The British journal of dermatology},
  doi = {10.1093/bjd/ljag403},
  url = {https://doi.org/10.1093/bjd/ljag403}
}

RIS

TY  - JOUR
TI  - Efficacy and Safety of Risankizumab in Paediatric Patients With Psoriasis in the OptIMMize-1 Phase III Study.
AU  - Magnolo N
AU  - Lara WL
AU  - Reich A
AU  - Lara-Corrales I
AU  - Morita A
AU  - Bukhalo M
AU  - Vicente A
AU  - Anschutz T
AU  - Lyles RD
AU  - Madihlaba T
AU  - Unnebrink K
AU  - Ashley D
AU  - Sharma D
AU  - D'Cunha R
AU  - Paller AS
PY  - 2026
JO  - The British journal of dermatology
DO  - 10.1093/bjd/ljag403
UR  - https://doi.org/10.1093/bjd/ljag403
ER  -

APA

N, M., WL, L., A, R., I, L., A, M., M, B., A, V., T, A., RD, L., T, M., K, U., D, A., D, S., R, D., & AS, P. (2026). Efficacy and Safety of Risankizumab in Paediatric Patients With Psoriasis in the OptIMMize-1 Phase III Study.. The British journal of dermatology. https://doi.org/10.1093/bjd/ljag403

Source records

pubmed · retrieved 2026-09-26T04:56:05.375Z